Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02311855 · ClinicalTrials.gov registry record · Phase 4
Duration of Immune Response to Influenza Vaccination in Patients With RA
A Phase 4 study, sponsored by Bassett Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
NCT02311855: Completed Phase 4 study, sponsored by Bassett Healthcare.
NCT02311855 is a Phase 4 study that has completed, run by Bassett Healthcare. The registered enrollment target is 87 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02311855, a Phase 4 study, has completed, sponsored by Bassett Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
Study Summary
The main objective is to evaluate the strength and duration of immune response after influenza vaccination in patients with Rheumatoid Arthritis (RA) receiving treatment with biological agents as compared to a group healthy controls who do not have RA. Influenza vaccine titers will be drawn 3 times: at Baseline(prior to vaccination), 4-6 weeks post vaccination, and 5-6 months post vaccination. Influenza vaccination will be done at the baseline visit after the baseline blood draw.
Primary Outcome
proportion of subjects with at least a 4-fold increase in titer at 4-6 weeks postvaccination to this year's influenza vaccine antigens;
Interventions
- BIOLOGICAL Influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 4 |
What the finished NCT02311855 record still lists
NCT02311855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Influenza vaccine is the first listed.
NCT02311855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02311855 about?
NCT02311855 is a clinical study titled "Duration of Immune Response to Influenza Vaccination in Patients With RA". The main objective is to evaluate the strength and duration of immune response after influenza vaccination in patients with Rheumatoid Arthritis (RA) receiving treatment with biological agents as compared to a group healthy controls who do not have RA. Influenza vaccine titers will be drawn 3 times:...
What is the current status of trial NCT02311855?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2014-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02311855?
The interventions under investigation include: Influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02311855?
This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02311855's enrollment target sits among peer trials
87 923rd of 2000 higher than 1,075 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia